Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting.

In 2005, Geoffrey Kempler was appointed CEO of Alterity Therapeutics Limited (ASX:ATH). This analysis aims first to...

It's nice to see the Alterity Therapeutics Limited (ASX:ATH) share price up 12% in a week. But spare a thought for the...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2020 (Q3 FY20).

Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...

In 2005 Geoffrey Kempler was appointed CEO of Alterity Therapeutics Limited (ASX:ATH). This report will, first...